Korro Bio
KRRO
43 hedge funds and large institutions have $2.52M invested in Korro Bio in 2023 Q1 according to their latest regulatory filings, with 7 funds opening new positions, 11 increasing their positions, 7 reducing their positions, and 12 closing their positions.
57% more repeat investments, than reductions
Existing positions increased: 11 | Existing positions reduced: 7
0.13% less ownership
Funds ownership: 0.42% → 0.28% (-0.13%)
10% less funds holding
Funds holding: 48 → 43 (-5)
29% less call options, than puts
Call options by funds: $37K | Put options by funds: $52K
42% less first-time investments, than exits
New positions opened: 7 | Existing positions closed: 12
91% less capital invested
Capital invested by funds: $28.1M → $2.52M (-$25.6M)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Acadian Asset Management
Boston,
Massachusetts
|
+$321K |
| 2 |
Simplex Trading
Chicago,
Illinois
|
+$168K |
| 3 |
Marshall Wace
London,
United Kingdom
|
+$155K |
| 4 |
Morgan Stanley
New York
|
+$146K |
| 5 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
+$89K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Federated Hermes
Pittsburgh,
Pennsylvania
|
-$5.05M |
| 2 |
WA
Wasatch Advisors
Salt Lake City,
Utah
|
-$2.9M |
| 3 |
GCP
GSA Capital Partners
London,
United Kingdom
|
-$1.02M |
| 4 |
Millennium Management
New York
|
-$386K |
| 5 |
BlackRock
New York
|
-$276K |
KRRO Hedge Fund Activity: Q1 2023 in Review
43 of the 6,283 institutional investors tracked by Wall St. Rank reported a position in Korro Bio (KRRO) for Q1 2023, worth a combined $2.52M — down 91% from $28.1M a quarter earlier.
Sellers outnumbered buyers: 12 funds closed out of KRRO and 7 opened new positions — a net loss of 5 holders — while 7 trimmed existing stakes and 11 added.
The largest buyer was Acadian Asset Management, opening a new position worth an estimated $321K. The largest seller was Federated Hermes, exiting entirely with an estimated $5.05M sold.
- 43 institutional investors held Korro Bio (KRRO) as of Q1 2023, down from 48 in Q4 2022.
- Funds reported $2.52M of Korro Bio stock for Q1 2023, down 91% quarter-over-quarter.
- 7 funds opened new Korro Bio positions in Q1 2023 and 12 closed out, a net change of -5 holders.
- The largest Korro Bio buyer in Q1 2023 was Acadian Asset Management, an estimated $321K added.
- The largest Korro Bio seller in Q1 2023 was Federated Hermes, an estimated $5.05M sold.
Based on aggregated 13F filings for Q1 2023.